Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
Trial status:Recruiting
Trial ID:
GCT1046-06
NCT ID:
EudraCT ID:
N/A
Sponsor:
The sponsor of a clinical trial is the company, institution or individual that takes responsibility for initiating, managing, and/or financing a clinical investigation. BioNTech collaborates with other pharmaceutical companies or institutions (collaborators) to develop certain new medicines. In particular cases BioNTech's collaborators are leading specific clinical trials and are acting as sponsors accordingly.
Genmab
Recruiting
Trial Details
This is a multicenter, randomized, open-label, international, Phase 3 trial to evaluate the efficacy and safety of acasunlimab in combination with pembrolizumab versus docetaxel (standard of care) in participants with programmed death ligand 1 (PD-L1)-positive metastatic non-small cell lung cancer (NSCLC) who have been treated with programmed cell death protein 1 (PD-1)/PD-L1 inhibitor and platinum-containing chemotherapy, administered either in combination or sequentially in the metastatic setting.
Medical Condition
Trial Drug
See more
Phase
Phase 3
Type
Interventional
Estimated Enrolment
702
Estimated Trial Date
Nov 2024 - Jan 2027
Trial Participant Requirements
Age
18+ years
Sex
Female & Male
Healthy Volunteers
No
Trial Locations
Location
Status
Location
Ocala Oncology Center P.L.
Ocala, Florida, United States, 34474
Status
Recruiting
Location
Norton Cancer Institute
Louisville, Kentucky, United States, 40202
Status
Recruiting
Location
Washington University School of Medicine
Saint Louis, Missouri, United States, 63110
Status
Recruiting
Location
Oncology Hematology West
Omaha, Nebraska, United States, 68124
Status
Recruiting
Location
Clinical Research Alliance
Westbury, New York, United States, 11590
Status
Recruiting
Location
Avera Cancer Institute
Sioux Falls, South Dakota, United States, 57105
Status
Recruiting